Pasireotide

Generic Name
Pasireotide
Brand Names
Signifor
Drug Type
Small Molecule
Chemical Formula
C58H66N10O9
CAS Number
396091-73-9
Unique Ingredient Identifier
98H1T17066
Background

Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

Indication

For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.

Associated Conditions
Acromegaly, Cushing's Disease
Associated Therapies
-
Clinical Trials
Related News

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

Completed
Conditions
Cushings Disease
Interventions
Drug: Pasireotide
First Posted Date
2014-12-08
Last Posted Date
2024-10-14
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
152
Registration Number
NCT02310269
Locations
🇨🇦

Centre de recherche du CHUM CRCHUM, Montreal, Quebec, Canada

🇨🇦

CHUS - Hopital Fleurimont, Sherbrooke, Quebec, Canada

🇨🇦

CHUL Centre de recherche du CHU, Quebec, Canada

and more 51 locations

Pasireotide in Prevention of GI Toxicity

Phase 2
Completed
Conditions
Hematological Malignancies
Interventions
Drug: Pasireotide
First Posted Date
2014-08-13
Last Posted Date
2021-11-17
Lead Sponsor
Anthony Sung, MD
Target Recruit Count
37
Registration Number
NCT02215070
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome

First Posted Date
2013-07-10
Last Posted Date
2013-07-10
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Target Recruit Count
9
Registration Number
NCT01895296
Locations
🇧🇪

University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

First Posted Date
2013-02-20
Last Posted Date
2024-10-01
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
337
Registration Number
NCT01794793
Locations
🇺🇸

University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States

🇮🇹

Milano Investigative Site, Milano, MI, Italy

🇺🇸

Ximed Research SC - SOM230B2412, La Jolla, California, United States

and more 6 locations

Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

First Posted Date
2012-06-15
Last Posted Date
2016-08-22
Lead Sponsor
Universidade Federal do Rio de Janeiro
Target Recruit Count
21
Registration Number
NCT01620138
Locations
🇧🇷

Endocrinology Section - Hospital Universitário Clementino Fraga Filho/Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil

Pasireotide Therapy in Patients With Nelson's Syndrome

Phase 2
Terminated
Conditions
Nelson Syndrome
Interventions
Drug: Pasireotide
First Posted Date
2012-06-12
Last Posted Date
2016-11-02
Lead Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Target Recruit Count
8
Registration Number
NCT01617733
Locations
🇬🇧

Barts and the London NHS Trust, London, United Kingdom

🇬🇧

The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

🇬🇧

Oxford University Hospitals NHS Trust, Oxford, United Kingdom

and more 1 locations

Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

First Posted Date
2011-12-08
Last Posted Date
2016-04-07
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
24
Registration Number
NCT01488487
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

🇺🇸

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

First Posted Date
2011-11-10
Last Posted Date
2018-10-18
Lead Sponsor
Emory University
Target Recruit Count
13
Registration Number
NCT01469572
Locations
🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

First Posted Date
2011-11-09
Last Posted Date
2021-03-25
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
18
Registration Number
NCT01468532
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: PLACEBO
Drug: PASIREOTIDE
First Posted Date
2011-05-20
Last Posted Date
2017-01-25
Lead Sponsor
Alliance Pour La Recherche en Cancerologie
Target Recruit Count
91
Registration Number
NCT01356862
Locations
🇫🇷

Institut Gustave ROUSSY, Villejuif, France

🇫🇷

Tenon Hospital, Paris, France

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy